Pharmacies in the United Kingdom have been found to frequently dispense weight-loss medications without adequately verifying patients’ body mass index (BMI), raising concerns over the safety and appropriateness of such prescriptions. This issue has intensified scrutiny of the growing use of GLP-1 receptor agonists, drugs commonly prescribed to aid weight loss.
Regulators as of September 2026 have received 216 reports of suspected deaths associated with these medications, linking the drugs as contributing factors in several cases. One such death involved a patient who suffered from septic shock and pancreatitis, with the weight-loss drug Mounjaro identified as a contributing agent. This case is considered the first official UK death connected to Mounjaro.
Experts warn that individuals with eating disorders are particularly vulnerable to adverse effects from these medications. Wera Hobhouse, a Liberal Democrat Member of Parliament and co-chair of the All-Party Parliamentary Group on Eating Disorders, expressed serious concerns following the findings. She highlighted that some patients appear to use appetite-suppressing drugs to intensify restrictive eating behaviors. Hobhouse emphasized the necessity for stringent safeguards, including face-to-face consultations, thorough screening for eating disorders, and appropriate psychological support before these medicines are prescribed. “Someone struggling with an eating disorder should not be able to access an appetite-suppressing drug without anyone asking what is driving their desire to lose weight,” she stated, noting the ongoing national eating disorder crisis.
The General Pharmaceutical Council (GPhC), responsible for regulating pharmacies in England, acknowledged concern over reports that some pharmacies are relying on photographs rather than independent verification of patients’ height and weight before supplying these drugs. Roz Gittins, the council’s chief pharmacy officer, stressed that relying solely on images to verify BMI is inappropriate and that pharmacies must conduct independent checks before prescribing weight-loss medications. The GPhC inspects hundreds of pharmacies monthly and is prepared to take regulatory action where necessary to ensure patient safety.
Some pharmacies have reportedly updated their procedures in response to these concerns. For instance, DoToR, an online provider of weight-loss medications, indicated that it no longer accepts uploaded images for verification due to advances in AI technology, which can manipulate images. Instead, the company now requires live camera images as part of the verification process.
Efforts to obtain comments from the government, the Medicines and Healthcare products Regulatory Agency (MHRA), and Roots, a weight-loss support provider, were unsuccessful at the time of reporting. However, the findings have prompted calls for a review of current protocols to prevent the misuse of these medications and ensure vulnerable patients receive appropriate care.
As the popularity of GLP-1 receptor agonists grows, medical professionals and patient advocates urge a balance between accessibility for those with genuine medical needs and rigorous safeguards to protect at-risk populations.